Global COVID-19 IgM/IgG Rapid Test Kits Market Size By Type (RDT(Rapid Diagnostic Test), ELISA(Enzyme-linked Immunosorbent Aassay)), By Application (Hospital, Special Clinic), By Region, And Segment F...

The Global COVID-19 IgM/IgG Rapid Test Kits Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 5.4 billion by 2031, growing at a CAGR of 7.3% from 2023 to 2031. The market is primarily driven by continued testing needs for surveillance, early diagnosis, and seroprevalence studies. These rapid test kits offer a critical diagnostic tool to detect antibodies generated due to SARS-CoV-2 infection and are widely used across point-of-care settings, especially in areas with limited access to centralized laboratories.

Drivers:

1. Sustained Demand for COVID-19 Monitoring and Surveillance:

Despite widespread vaccination, ongoing variants and breakthrough infections necessitate persistent antibody testing to monitor immunity levels, contributing to consistent demand for IgM/IgG rapid test kits.

2. Rising Preference for Point-of-Care Diagnostics:

The simplicity, speed, and portability of rapid antibody test kits make them ideal for mass screenings, rural outreach programs, and non-laboratory healthcare environments, propelling market growth.

3. Government and Institutional Initiatives:

Various health agencies and governments continue funding seroprevalence studies, long-term COVID surveillance, and public health diagnostics, increasing procurement of rapid IgM/IgG kits.

Restraints:

1. Reduced Urgency Post-Vaccine Rollout:

With declining hospitalization rates and increased reliance on PCR or antigen testing, demand for antibody testing has seen a decline in some regions, restraining short-term growth.

2. Inconsistent Accuracy and Regulatory Scrutiny:

Sensitivity and specificity issues with some test kits have led to fluctuating regulatory approvals, impacting manufacturer credibility and limiting adoption in clinical settings.

Opportunity:

1. Expansion into Low-Resource and Emerging Markets:

Emerging economies and rural healthcare systems still lack access to centralized testing, creating strong demand for rapid, easy-to-administer antibody tests.

2. Development of Multiplex Testing Platforms:

Innovation in combining IgM/IgG testing with antigen or flu diagnostics in one device represents a significant growth opportunity for kit manufacturers.

Market by System Type Insights:

The market is segmented into Lateral Flow Assays (LFAs) and Enzyme-Linked Immunosorbent Assays (ELISA)-based rapid tests. In 2023, Lateral Flow Assays accounted for the largest share due to their affordability, ease of use, and quick results. However, ELISA-based rapid kits are gaining traction for their superior accuracy and application in semi-quantitative antibody profiling.

Market by End-Use Insights:

Based on end-use, the Diagnostic Laboratories segment dominated the market in 2023. These labs extensively utilize IgM/IgG rapid kits for large-scale testing, seroprevalence studies, and screening unvaccinated or exposed populations. Meanwhile, the Homecare & Self-testing segment is witnessing rapid growth, spurred by over-the-counter approvals and the rise of consumer-driven healthcare.

Market by Regional Insights:

Asia-Pacific led the market in 2023, driven by large-scale community testing initiatives, high population density, and governmental efforts in surveillance. North America follows closely, with robust public health infrastructure and high public awareness. The Middle East & Africa region is poised for the fastest growth, supported by foreign aid programs and expanding healthcare infrastructure.

Competitive Scenario:

Key market players include Abbott Laboratories, F. Hoffmann-La Roche AG, Cellex Inc., SD Biosensor Inc., BioMedomics Inc., Hangzhou Biotest Biotech Co., Ltd., and ACON Laboratories Inc. These companies are focusing on strategic collaborations, regional expansion, and the development of multiplexed and high-sensitivity testing kits.

Scope of Work – Global COVID-19 IgM/IgG Rapid Test Kits Market

Report Metric Details

Market Size (2023) USD 3.1 billion

Projected Market Size (2031) USD 5.4 billion

CAGR (2023–2031) 7.3%

Market Segments System Type (LFA, ELISA), End-use (Labs, Hospitals,